Analyst	Recommendation	Action	Price target	Projected	Date
Vamil Divan Guggenheim	Buy	Maintained	$11.00	+238.5%	11/09/2026
Patrick Dolezal LifeSci Capital	Buy	Maintained	$10.00	+207.7%	10/14/2026
Imogen Mansfield Cantor Fitzgerald	Buy	Initiated	-	-	09/22/2026
David Risinger Leerink Partners	Buy	Initiated	$9.00	+176.9%	09/18/2026
Ram Selvaraju H.C. Wainwright	Buy	Reiterated	$9.00	+176.9%	06/24/2026

All values in USD	Dec 2025	Mar 2026	Jun 2026	Sep 2026
Revenue	-	-	-	-
Cost of goods sold	-	-	-	-
Cost of revenue	-	-	-	-
Research and development expenses	1.72M	2.25M	3.20M	4.92M
Total research and development expenses	-	-	-	-
Selling, general, and admin expenses	1.32M	1.29M	1.36M	2.34M
Operating expense	3.04M	3.54M	4.56M	7.26M
Total operating expenses	3.04M	3.54M	4.56M	7.26M
Operating income	-3.04M	-3.54M	-4.56M	-7.26M
Other non operating income	-	-	-	-
EBT including unusual items	-3.02M	-3.50M	-7.31M	-15.60M
EBT excluding unusual items	-3.02M	-3.50M	-7.31M	-15.60M
Income tax expense	-	-	-	-
Effective tax rate	-	-	-	-
Other operating expenses	-	-	-	-
Net income	-3.02M	-3.50M	-7.31M	-15.60M
Net profit margin	-	-	-	-
Earnings per share	-	-	-	-
Interest and investment income	26.00K	34.00K	-	-
Interest expense	-	-	-2.75M	-8.33M
Net interest expenses	26.00K	34.00K	-2.75M	-8.33M
Depreciation and amortization charges	-	-	-	-
EBITDA	-3.04M	-3.53M	-4.55M	-7.26M
Gain or loss from assets sale	-	-	-	-

Ask anything